Peer-reviewed veterinary case report
Masitinib treatment results for dogs with epitheliotropic lymphoma
By Holtermann, N. et al.·Published in Veterinary and Comparative Oncology·2015·Medizinische Kleintierklinik Ludwig Maximilians University Munich Munich Germany, Germany·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Masitinib monotherapy in canine epitheliotropic lymphoma
- Species:
- dog
Plain-English summary
A group of dogs with a type of skin cancer called epitheliotropic lymphoma were treated with a medication called masitinib to see how well it worked. Out of ten dogs, two went into complete remission for about 85 days, while five had partial remission lasting around 60 days. Some dogs experienced mild to moderate side effects, but overall, masitinib showed promise as a treatment option. If your dog has this type of lymphoma, discussing masitinib with your veterinarian might be worthwhile.
People also search for: dog skin cancer treatment · masitinib for canine lymphoma · epitheliotropic lymphoma in dogs
Abstract
AbstractThis study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs.KITreceptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet‐derived growth factor (PDGF)‐AAwas weakly positive in two and negative in six.PDGF‐BBwas negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)‐β, seven were negative for that receptor. Five showed strong expression ofPDGFR‐α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through theKITreceptor.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12157